Pfizer's Weight-Loss Data Just Upends Investor Bets
Pfizer is stepping into a high-stakes arena long led by Lilly and Novo Nordisk. This article analyzes what pfizer's w...
Starting your investment journey? Learn what to watch out for as a new investor to avoid common pitfalls and make wise choices.
27,620 articlesPfizer is stepping into a high-stakes arena long led by Lilly and Novo Nordisk. This article analyzes what pfizer's w...
As HMBS 2.0 stalls and a 98% buyout rule tightens liquidity, Longbridge Financial’s Tim Wilkinson explains how privat...
A flood of political spending from crypto firms aimed at shaping new laws has investors eyeing policy risk. This guid...
A major fund just disclosed a sizable stake in Tango Therapeutics (TNGX), totaling about $9.5 million. This move shin...
Three practical lessons from SpaceX’s IPO can guide investors as Anthropic and OpenAI approach the market. Learn how ...
IP Strategy said its board approved a buyback of up to 1,000,000 common shares through Dec. 31, 2026, potentially tri...
A late 2025 survey shows fix-and-flip investor sentiment climbs even as flipping activity falls to decade lows, signa...
Nvidia delivers a standout quarter powered by AI demand, surpassing estimates and lifting guidance. This article brea...
Paramount’s move to revive G.I. Joe with a controversial hire is more than a movie decision—it’s a case study in risk...
SpaceX IPO chatter has investors buzzing and critics worried. This piece breaks down why the hype could outpace reali...
SpaceX's public debut created big waves, but a recent pullback has many investors asking if it’s time to buy. This ar...
A clear guide to reading RMTI's Q1 2026 earnings call, what the numbers mean, and how to spot the catalysts that can ...